Skip to Content

Changes in Cancer Incidence, Deaths Expected by 2040

THURSDAY, April 8, 2021 -- Cancer incidence and death are expected to change by 2040, with breast cancer remaining the most common cancer followed by melanoma, then lung cancer, according to a study published online April 7 in JAMA Network Open.

Lola Rahib, Ph.D., from Cancer Commons in Mountain View, California, and colleagues used population growth projections and current population-based cancer incidence and death rates to calculate the changes in incidences and deaths to 2040.

The researchers estimated that the most common cancers in 2040 will be breast cancer, melanoma, and lung cancer (364,000; 219,000; and 208,000 cases, respectively), followed by colorectal cancer as the fourth most common (147,000 cases) and prostate cancer as the 14th most common (66,000 cases). In 2040, lung cancer is expected to continue as the leading cause of cancer-related death, followed by pancreatic cancer (63,000 and 46,000 deaths, respectively), while liver and intrahepatic bile duct cancer were expected to surpass colorectal cancer (41,000 and 34,000 deaths, respectively). Breast cancer was expected to decrease to the fifth most common cause of death (30,000 deaths).

"The estimated absolute number of cancer diagnoses and deaths will be important to inform the need for professionals trained to recognize and care for individuals with the disease, the burden on insurance companies and government programs, and the allocation of research funding to support future prevention and treatments," the authors write.

Abstract/Full Text

© 2021 HealthDay. All rights reserved.

Read this next

Cutaneous AEs Linked to Immune Checkpoint Inhibitor Therapy

TUESDAY, April 20, 2021 -- Cutaneous immune-related adverse events (irAEs) are associated with initiation of immune checkpoint inhibitor (ICI) treatment in cancer patients,...

Chronic Adverse Effects From Anti-PD-1 Immunotherapies Common

FRIDAY, April 16, 2021 -- Chronic immune-related adverse effects after adjuvant treatment with anti-programmed cell death 1 (anti-PD-1) immunotherapies for melanoma are more...

Risk-Based Approach Developed to Triage Mammography Use

FRIDAY, April 16, 2021 -- Clinical indication and individual risk factors are associated with breast cancer detection and could help triage mammography examinations, according to...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.